Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Vaccine

Volumn 35, Issue 32, 2017, Pages 3922-3929

  Bissett, Sara L ^a   Godi, Anna ^a   Jit, Mark ^a,b   Beddows, Simon ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibody; Human papillomavirus; Meta analysis; Systematic review; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; META ANALYSIS; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VACCINE IMMUNOGENICITY; WART VIRUS; CLASSIFICATION; CROSS REACTION; GENETICS; GENOTYPE; IMMUNOLOGY; PAPILLOMAVIRIDAE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 85020518542     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.06.028     Document Type: Article

References (44)

1. de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., Plummer, M., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13 (2012), 607–615.
2. Schiller, J.T., Lowy, D.R., Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 10 (2012), 681–692.
3. de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11 (2010), 1048–1056.
4. Lehtinen, M., Dillner, J., Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 10 (2013), 400–410.
5. Schiller, J.T., Castellsague, X., Garland, S.M., A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:Suppl 5 (2012), F123–F138.
6. Di Mario, S., Basevi, V., Lopalco, P.L., Balduzzi, S., D'Amico, R., Magrini, N., Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res, 2015, 2015, 435141.
7. Drolet, M., Benard, E., Boily, M.C., Ali, H., Baandrup, L., Bauer, H., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
8. Kemp, T.J.A., Garcia-Pineres, R.T., Falk, S., Poncelet, F., Dessy, S.L., Giannini, A.C., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine. 26 (2008), 3608–3616.
9. Breitburd, F., Kirnbauer, R., Hubbert, N.L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995), 3959–3963.
10. Suzich, J.A., Ghim, S.J., Palmer-Hill, F.J., White, W.I., Tamura, J.K., Bell, J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 92 (1995), 11553–11557.
11. Longet, S., Schiller, J.T., Bobst, M., Jichlinski, P., Nardelli-Haefliger, D., A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85 (2011), 13253–13259.
12. Malagon, T., Drolet, M., Boily, M.C., Franco, E.L., Jit, M., Brisson, J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 781–789.
13. Mesher, D., Soldan, K., Lehtinen, M., Beddows, S., Brisson, M., Brotherton, J.M., et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 22 (2016), 1732–1740.
14. Draper, E., Bissett, S.L., Howell-Jones, R., Waight, P., Soldan, K., Jit, M., et al. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12–15 year old girls. PLoS One., 8, 2013, e61825.
15. Kemp, T.J., Hildesheim, A., Safaeian, M., Dauner, J.G., Pan, Y., Porras, C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29 (2011), 2011–2014.
16. Draper, E., Bissett, S.L., Howell-Jones, R., Edwards, D., Munslow, G., Soldan, K., et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29 (2011), 8585–8590.
17. Einstein, M.H., Baron, M., Levin, M.J., Chatterjee, A., Fox, B., Scholar, S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin. 7 (2011), 1359–1373.
18. Toft, L., Tolstrup, M., Muller, M., Sehr, P., Bonde, J., Storgaard, M., et al. Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vaccin Immunother. 10 (2014), 1147–1154.
19. Barzon, L., Squarzon, L., Masiero, S., Pacenti, M., Marcati, G., Mantelli, B., et al. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Vaccine. 32 (2014), 5357–5362.
20. Herrin, D.M., Coates, E.E., Costner, P.J., Kemp, T.J., Nason, M.C., Saharia, K.K., et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother. 10 (2014), 3446–3454.
21. Efron, B., Tibshirani, R.J., An Introduction to the Bootstrap. Monographs on statistics and applied probability 57. 1994, Chapman and Hall/CRC.
22. Einstein, M.H., Baron, M., Levin, M.J., Chatterjee, A., Fox, B., Scholar, S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 7 (2011), 1343–1358.
23. Toft, L., Storgaard, M., Muller, M., Sehr, P., Bonde, J., Tolstrup, M., et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 209 (2014), 1165–1173.
24. Wheeler, C.M., Castellsague, X., Garland, S.M., Szarewski, A., Paavonen, J., Naud, P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 (2012), 100–110.
25. Brown, D.R., Kjaer, S.K., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Wheeler, C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 199 (2009), 926–935.
26. Safaeian, M., Kemp, T.J., Pan, D.Y., Porras, C., Rodriguez, A.C., Schiffman, M., et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother 9 (2013), 1399–1406.
27. Block, S.L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K.E., Marchant, C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006), 2135–2145.
28. Dobson, S.R., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Jama. 309 (2013), 1793–1802.
29. Romanowski, B., Schwarz, T.F., Ferguson, L.M., Peters, K., Dionne, M., Schulze, K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 7 (2011), 1374–1386.
30. Sow, P.S., Watson-Jones, D., Kiviat, N., Changalucha, J., Mbaye, K.D., Brown, J., et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-Seronegative African girls and young women. J Infect Dis 207 (2013), 1753–1763.
31. Levin, M.J., Huang, S., Moscicki, A.B., Song, L.Y., Read, J.S., Meyer, W.A., et al. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine. Vaccine. 35 (2017), 1712–1720.
32. Einstein, M.H., Takacs, P., Chatterjee, A., Sperling, R.S., Chakhtoura, N., Blatter, M.M., et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 10 (2014), 3435–3445.
33. Toh, Z.Q., Licciardi, P.V., Fong, J., Garland, S.M., Tabrizi, S.N., Russell, F.M., et al. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Vaccine. 33 (2015), 5042–5050.
34. Basu, P., Bhatla, N., Ngoma, T., Sankaranarayanan, R., Less than 3 doses of the HPV vaccine – review of efficacy against virological and disease end points. Hum Vaccin Immunother 12 (2016), 1394–1402.
35. WHO, Meeting of the strategic advisory group of experts (SAGE) on immunization – conclusions and recommendations. Weekly Epidemiological Record 2014:89 (2014), 221–236.
36. Safaeian, M., Porras, C., Pan, Y., Kreimer, A., Schiller, J.T., Gonzalez, P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 6 (2013), 1242–1250.
37. Kreimer, A.R., Struyf, F., Del Rosario-Raymundo, M.R., Hildesheim, A., Skinner, S.R., Wacholder, S., et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 16 (2015), 775–786.
38. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
39. Iversen, O.E., Miranda, M.J., Ulied, A., Soerdal, T., Lazarus, E., Chokephaibulkit, K., et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. Jama 316 (2016), 2411–2421.
40. Herrero, R., Gonzalez, P., Markowitz, L.E., Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 16 (2015), e206–e216.
41. Drolet, M., Laprise, J.F., Boily, M.C., Franco, E.L., Brisson, M., Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 134 (2014), 2264–2268.
42. Brisson, M., Laprise, J.F., Chesson, H.W., Drolet, M., Malagon, T., Boily, M.C., et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst, 108, 2016.
43. Joura, E., Bautista, O., Luxembourg, A., A 9-valent HPV vaccine in women. N Engl J Med 372 (2015), 2568–2569.
44. Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F.X., et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. The Lancet Global health. 4 (2016), e453–e463.